At Epi One, we’re on a mission to revolutionize how cancer is detected and diagnosed. During our recent webinar, our CEO, Michael Marquardt, and fellow healthcare executive and lead investor, Daniel Etra, shared exciting updates about our progress and vision for the future.
In case you missed the webinar, you can watch the full replay here: https://youtu.be/u3XjHg9JrMM
Our Breakthrough Technology
Our DNA-based technology represents a fundamental shift in cancer detection. While many companies are focused on whole genome sequencing, we’ve discovered a novel approach using epigenetics. As our CEO Michael Marquardt explained, it’s like finding the exact frequency on a radio dial – we know precisely where to look for cancer’s molecular fingerprint, allowing us to detect it earlier and more accurately than ever.
Clinical Validation Success
We’re proud to report that our clinical validations have consistently shown remarkable results:
- 93-96% sensitivity and specificity rates
- Validated across multiple cancer types
- Successfully tested on 400+ samples, with expansion planned
- First patent was issued, with additional patents in progress
Rapid Progress Towards Market
We’re accelerating our path to market with several key initiatives:
- Establishing our CLIA-certified laboratory
- Planning our first commercial test launch in Q3/Q4 2025
- Developing partnerships with healthcare providers and labs in the US and abroad
- Pursuing FDA approval for mass-produced tests
Why Our Approach is Different
Our technology stands apart in several crucial ways:
- Results in hours instead of weeks
- Planned pricing well under $1,000
- Ability to detect cancer aggressiveness levels
- Scalable for global deployment
Join Our Journey
As we approach this pivotal moment in our company’s history, we’re building a broad base of supporters who share our vision of transforming cancer diagnosis worldwide. Our StartEngine campaign closes very soon, and we’re hosting a final webinar on November 26th at 4:30 PM Eastern with our brilliant Co-Founder Dr. Sophia Fang.
We invite you to be part of this groundbreaking effort to save lives through earlier cancer detection. There’s a limited window of time left to join our investor community during this round.
Together, we can make early cancer detection more accurate, affordable, and accessible for millions of people around the world.
For those interested in learning more about investment opportunities, please visit our campaign page on Start Engine as soon as possible because our campaign is closing very soon.
